Case Report
BibTex RIS Cite

Year 2018, Volume: 35 Issue: 1, 27 - 30, 25.10.2019

Murat Terzi Taşkın Duman Sedat Şen Murat Güntel Nalan Örtücü Şen

Abstract

References

  • Ahmed, A.M., Brantley, J.S., Madkan, V., Mendoza, N., Tyring, S.K., 2007. Managing herpes zoster in immunocompromised patients. Herpes. 14, 32-6.
  • Bennett, G.J., 1994. Hypotheses on the pathogenesis of herpes zoster associated pain. Ann Neurol. 35, 38-41.
  • Brody, M.B., Moyer, D., 1997. Varicella-zoster virus infection. Postgrad Med. 102(1), 187–94.
  • Cohen, J.I., Brunell, P.A., Straus, S.E., Krause, P.R., 1999. Recent advances in varicella-zoster virus infection. Ann Intern Med.130, 922-32.
  • Cohen, J.A., Barkhof, F., Comi, G., Hartung, H.P., Khatri, B.O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., Tiel-Wilck, K., de Vera, A., Jin, J., Stites, T., Wu, S., Aradhye, S., Kappos, L., Transforms Study Group., 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 362, 402-15.
  • Dworkin, R.H., Johnson, R.W., Breuer, J., Gnann, J.W., Levin, M.J., Backonja, M., Betts, R.F., Gershon, A.A., Haanpaa, M.L., McKendrick, M.W., Nurmikko, T.J., Oaklander, A.L., Oxman, M.N., Pavan-Langston, D., Petersen, K.L., Rowbotham, M.C., Schmader, K.E., Stacey, B.R., Tyring, S.K., van Wijck, A.J., Wallace, M.S., Wassilew, S.W., Whitley, R.J., 2007. Recommendations for the management of herpes zoster. Clin Infect Dis. 44(1), 1-26.
  • Gnann, J.W. Jr., Whitley, R.J., 2002. Clinical practice: herpes zoster. N Engl J Med. 347, 340-6. Kappos, L., Radue, E.W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang- Auberson, L., Burtin, P., Freedoms Study Group., 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 362, 387-401.
  • Ricklin, M.E., Lorscheider, J., Waschbisch, A., Paroz, C., Mehta, S.K., Pierson, D.L., Kuhle, J., Fischer-Barnicol, B., Sprenger, T., Lindberg, R.L., Kappos, L., Derfuss, T., 2013. T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology. 9, 81(2), 174-81.
  • Strauss, S.E., 1994. Overview: the biology of varicella-zoster virus infection. Ann Neurol. 35, 4–8.
  • Uccelli, A., Ginocchio, F., Mancardi, G.L., Bassetti, M., 2011. Primary varicella zoster infection associated with fingolimod treatment.Neurology. 15, 76(11), 1023-4.
  • Weinberg, J.M., 2007. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol. 57, 130-5. Winkelmann, A., Löbermann, M., Reisinger, E.C., Zettl, U.K. 2012. Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations. Nervenarzt. 83(2), 236-42.

Two multiple sclerosis cases developed herpes zoster during use of fingolimod

Year 2018, Volume: 35 Issue: 1, 27 - 30, 25.10.2019

Murat Terzi Taşkın Duman Sedat Şen Murat Güntel Nalan Örtücü Şen

Abstract




Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central
nervous system. Immunosuppressive and immunomodulating drugs are used
during disease monitoring. Fingolimod is one of the immunomodulatory treat-
ments used in MS patients. It is a therapeutic agent acting on lymphocytes. La-
tent varicella-zoster virus infections may occur in MS patients receiving fingo-
limod therapy. In this article, the information of two cases with varicella-zoster
virus reactivation during fingolimod use were presented.




Keywords

Fingolimod Multiple sclerosis Varicella-zoster virus reactivation Zoster

References

  • Ahmed, A.M., Brantley, J.S., Madkan, V., Mendoza, N., Tyring, S.K., 2007. Managing herpes zoster in immunocompromised patients. Herpes. 14, 32-6.
  • Bennett, G.J., 1994. Hypotheses on the pathogenesis of herpes zoster associated pain. Ann Neurol. 35, 38-41.
  • Brody, M.B., Moyer, D., 1997. Varicella-zoster virus infection. Postgrad Med. 102(1), 187–94.
  • Cohen, J.I., Brunell, P.A., Straus, S.E., Krause, P.R., 1999. Recent advances in varicella-zoster virus infection. Ann Intern Med.130, 922-32.
  • Cohen, J.A., Barkhof, F., Comi, G., Hartung, H.P., Khatri, B.O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., Tiel-Wilck, K., de Vera, A., Jin, J., Stites, T., Wu, S., Aradhye, S., Kappos, L., Transforms Study Group., 2010. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 362, 402-15.
  • Dworkin, R.H., Johnson, R.W., Breuer, J., Gnann, J.W., Levin, M.J., Backonja, M., Betts, R.F., Gershon, A.A., Haanpaa, M.L., McKendrick, M.W., Nurmikko, T.J., Oaklander, A.L., Oxman, M.N., Pavan-Langston, D., Petersen, K.L., Rowbotham, M.C., Schmader, K.E., Stacey, B.R., Tyring, S.K., van Wijck, A.J., Wallace, M.S., Wassilew, S.W., Whitley, R.J., 2007. Recommendations for the management of herpes zoster. Clin Infect Dis. 44(1), 1-26.
  • Gnann, J.W. Jr., Whitley, R.J., 2002. Clinical practice: herpes zoster. N Engl J Med. 347, 340-6. Kappos, L., Radue, E.W., O’Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang- Auberson, L., Burtin, P., Freedoms Study Group., 2010. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 362, 387-401.
  • Ricklin, M.E., Lorscheider, J., Waschbisch, A., Paroz, C., Mehta, S.K., Pierson, D.L., Kuhle, J., Fischer-Barnicol, B., Sprenger, T., Lindberg, R.L., Kappos, L., Derfuss, T., 2013. T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Neurology. 9, 81(2), 174-81.
  • Strauss, S.E., 1994. Overview: the biology of varicella-zoster virus infection. Ann Neurol. 35, 4–8.
  • Uccelli, A., Ginocchio, F., Mancardi, G.L., Bassetti, M., 2011. Primary varicella zoster infection associated with fingolimod treatment.Neurology. 15, 76(11), 1023-4.
  • Weinberg, J.M., 2007. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol. 57, 130-5. Winkelmann, A., Löbermann, M., Reisinger, E.C., Zettl, U.K. 2012. Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations. Nervenarzt. 83(2), 236-42.
There are 11 citations in total.

Details

Primary Language English
Journal Section Case Report
Authors

Murat Terzi

Taşkın Duman This is me

Sedat Şen This is me

Murat Güntel This is me

Nalan Örtücü Şen This is me

Publication Date October 25, 2019
Submission Date December 10, 2015
Acceptance Date February 28, 2016
Published in Issue Year 2018 Volume: 35 Issue: 1

Cite

APA Terzi, M., Duman, T., Şen, S., Güntel, M., et al. (2019). Two multiple sclerosis cases developed herpes zoster during use of fingolimod. Journal of Experimental and Clinical Medicine, 35(1), 27-30.
AMA Terzi M, Duman T, Şen S, Güntel M, Örtücü Şen N. Two multiple sclerosis cases developed herpes zoster during use of fingolimod. J. Exp. Clin. Med. October 2019;35(1):27-30.
Chicago Terzi, Murat, Duman Taşkın, Sedat Şen, Murat Güntel, and Örtücü Şen Nalan. “Two Multiple Sclerosis Cases Developed Herpes Zoster During Use of Fingolimod”. Journal of Experimental and Clinical Medicine 35, no. 1 (October 2019): 27-30.
EndNote Terzi M, Duman T, Şen S, Güntel M, Örtücü Şen N (October 1, 2019) Two multiple sclerosis cases developed herpes zoster during use of fingolimod. Journal of Experimental and Clinical Medicine 35 1 27–30.
IEEE M. Terzi, T. Duman, S. Şen, M. Güntel, and Örtücü Şen N., “Two multiple sclerosis cases developed herpes zoster during use of fingolimod”, J. Exp. Clin. Med., vol. 35, no. 1, pp. 27–30, 2019.
ISNAD Terzi, Murat et al. “Two Multiple Sclerosis Cases Developed Herpes Zoster During Use of Fingolimod”. Journal of Experimental and Clinical Medicine 35/1 (October 2019), 27-30.
JAMA Terzi M, Duman T, Şen S, Güntel M, Örtücü Şen N. Two multiple sclerosis cases developed herpes zoster during use of fingolimod. J. Exp. Clin. Med. 2019;35:27–30.
MLA Terzi, Murat et al. “Two Multiple Sclerosis Cases Developed Herpes Zoster During Use of Fingolimod”. Journal of Experimental and Clinical Medicine, vol. 35, no. 1, 2019, pp. 27-30.
Vancouver Terzi M, Duman T, Şen S, Güntel M, Örtücü Şen N. Two multiple sclerosis cases developed herpes zoster during use of fingolimod. J. Exp. Clin. Med. 2019;35(1):27-30.
 Download Cover Image

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.